The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Ovarian cancer stem cells express ROR1, which can be targeted for anti–cancer-stem-cell therapy
Open accessAbstract
Significance: This study demonstrates that the oncoembryonic surface antigen, receptor tyrosine kinase-like orphan receptor 1 (ROR1), is expressed on human ovarian cancer stem cells (CSCs), on which it seems to play a functional role in promoting migration/invasion or spheroid formation in vitro and tumor engraftment in immune-deficient mice. Treatment with a humanized mAb specific for ROR1 (UC-961) could inhibit the capacity of ovarian cancer cells to migrate, form spheroids, or engraft immune-deficient mice. Moreover, such treatment inhibited the growth of tumor xenografts, which in turn had a reduced capacity to engraft immune-deficient mice and were relatively depleted of cells with features of CSC, suggesting that treatment with UC-961 could impair CSC renewal. Collectively, these studies indicate that ovarian CSCs express ROR1, which may be targeted for anti-CSC therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Self-renewal as a therapeutic target in human colorectal cancer
Kreso, A., van Galen, P., Pedley, N. M., Lima-Fernandes, E., Frelin, C., Davis, T., Cao, L., Baiazitov, R., Du, W., Sydorenko, N., et al. (2014) · Nature Medicine · doi:10.1038/nm.3418 · Cited by 500
Bmi1, stem cells, and senescence regulation
Park, I.-K., Morrison, S. J., & Clarke, M. F. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420800 · Cited by 495 · cited 1×
“Furthermore, silencing ROR1 reduced expression of Bmi-1, the polycomb ring-finger oncogene that regulates CSC self-renewal (38, 39).”
BackgroundYamaguchi, T., Yanagisawa, K., Sugiyama, R., Hosono, Y., Shimada, Y., Arima, C., Kato, S., Tomida, S., Suzuki, M., Osada, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.008 · Cited by 249
The Onco-Embryonic Antigen ROR1 Is Expressed by a Variety of Human Cancers
Zhang, S., Chen, L., Wang-Rodriguez, J., Zhang, L., Cui, B., Frankel, W., Wu, R., & Kipps, T. J. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.08.024 · Cited by 207
Self-citationTargeting ROR1 Inhibits Epithelial–Mesenchymal Transition and Metastasis
Cui, B., Zhang, S., Chen, L., Yu, J., Widhopf, G. F., Fecteau, J.-F., Rassenti, L. Z., & Kipps, T. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3832 · Cited by 187 · cited 16×
“Moreover, silencing ROR1 protein expression inhibited the expression level of EMT markers (e.g., N-cadherin and vimentin) and SNAIL1/2, master regulators of EMT (Fig.”
BackgroundInfluentialSelf-citation
Cited by
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Bowtell, D. D., Böhm, S., Ahmed, A. A., Aspuria, P.-J., Bast, R. C., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S., Bookman, M. A., et al. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4019 · Cited by 1,367
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074
EMT, CTCs and CSCs in tumor relapse and drug-resistance
Mitra, A., Mishra, L., & Li, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4037 · Cited by 465
Katoh, M. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4129 · Cited by 465
Epithelial–mesenchymal transition: a new target in anticancer drug discovery
Marcucci, F., Stassi, G., & De Maria, R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.13 · Cited by 342
Metadata
- Authors
- Zhang, S., Cui, B., Lai, H., Liu, G., Ghia, E. M., Widhopf, G. F., Zhang, Z., Wu, C. C. N., Chen, L., Wu, R., Schwab, R., Carson, D. A., & Kipps, T. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2014-11-19
- Volume
- 111
- Issue
- 48
- Pages
- 17266-17271
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2092864627
- Cited by
- 186
- References
- 6
- FWCI
- 7.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.